Aoyama Renacell Clinic to Expand Facility with New Cell Processing Center

Production of proprietary stem cell culture supernatant solution Focusing on plasma regenerative medicine demonstration experiments with Tokyo Institute of Technology

2024.06.26 10:30

一般社団法人輝実会青山レナセルクリニック

Aoyama Renacell Clinic (2-7-28 Kita-Aoyama, Minato-ku, Tokyo, Japan) has recently expanded its facilities to another floor in the same building and opened a new sterile cell culture room ("Aoyama Cell Processing Center").

The center has already received approval from the public health center and the Ministry of Health, Labour, and Welfare's committee for the provision of regenerative medicine, and will have a pre-opening on Tuesday, June 25 and a grand opening on Tuesday, July 2.

Since its opening in June 2020, the clinic has steadily expanded its business over the past four years, and has outgrown its current facility on the 5th floor, so it was decided to add another floor (approximately 240 square meters) in anticipation of future increases in inbound patients.

Since the time of its predecessor, Akasaka Renacelle Clinic, which had both medical and dental facilities, the clinic has focused on deciduous tooth pulp-derived stem cell culture and supernatant therapy (exosome therapy), and has the largest number of treatments (over 2,000ml/month) in Japan, and has abundant clinical expertise in this field.

With the recent establishment of the Aoyama Cell Processing Center, we will produce and provide patients with the highest specification of deciduous dental pulp stem cell culture supernatant solution (exosome) based on our own production protocol under the supervision of a professional in dental pulp stem cell culture and a "senior clinical culturer" certified by the Japanese Society for Regenerative Medicine.

In addition, as of February 1, 2024, the clinic has started joint research with the Okino Laboratory of the Tokyo Institute of Technology for the application of atmospheric pressure low-temperature plasma to the field of regenerative medicine, and has successfully developed a medical jet device "Renacell Hyper Plasma" (trademark registration pending) that can produce about 150,000 times lower temperature plasma than conventional products The Aoyama Cell Processing Center has succeeded in developing the "Renacell Hyper Plasma" (trademark registration pending), a medical jet device capable of producing low-temperature plasma 150,000 times more powerful than conventional products.

The Aoyama Cell Processing Center plans to use this device to conduct demonstration experiments on the improvement of stem cell proliferation ability and changes in the mass of cytokines secreted by stem cells due to the irradiation of low-temperature plasma.

Official HP of Okino Laboratory, Tokyo Institute of Technology

https://ap.first.iir.titech.ac.jp/